天宇股份(300702) - 2025 Q2 - 季度业绩预告

2025 Semi-Annual Performance Forecast Overview Zhejiang Tianyu Pharmaceutical anticipates significant net profit growth in H1 2025, with preliminary estimates indicating a substantial increase in both attributable and non-recurring net profits I. Current Period Performance Forecast Zhejiang Tianyu Pharmaceutical expects net profit attributable to shareholders to increase significantly by 144.29% to 238.25% in H1 2025, with non-recurring net profit growing 92.79% to 172.45%, indicating strong performance 2025 Semi-Annual Performance Forecast | Item | Estimated Profit for Current Period (Million CNY) | Profit in Same Period Last Year (Million CNY) | Year-over-Year Growth Rate | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 130 – 180 | 53.2152 | 144.29% - 238.25% | | Net Profit Excluding Non-Recurring Items | 121 – 171 | 62.764 | 92.79% - 172.45% | II. Pre-Audit Status of Performance Forecast This performance forecast is a preliminary estimate by the company's finance department and has not been audited by an accounting firm - This performance forecast has not been audited by an accounting firm[4] Analysis of Performance Change Reasons The company's strong performance is attributed to strategic market engagement, operational efficiencies, product optimization, and reduced foreign exchange losses, complemented by government subsidies III. Explanation of Performance Change Reasons During the reporting period, significant performance growth was primarily driven by seizing market opportunities, expanding customer channels, strengthening refined management, optimizing product structure, improving market layout, and enhancing cost control, leading to increased main business revenue and gross profit; additionally, a substantial reduction in foreign exchange derivative transactions effectively lowered losses, and non-recurring income from government subsidies was received - The company actively seized market opportunities, continuously expanded customer channels, and strengthened refined management, further enhancing its core competitiveness[5] - In main business expansion, measures such as optimizing product structure, improving market layout, and strengthening cost control effectively boosted revenue and gross profit growth for the company's non-sartan APIs and intermediates, CDMO, and pharmaceutical preparation businesses[5] - The company significantly reduced foreign exchange derivative transaction volumes, effectively lowering losses[5] - During the reporting period, non-recurring gains and losses are expected to impact net profit attributable to listed company shareholders by approximately 9 million CNY, primarily due to government subsidies[5] Risk Warning and Subsequent Disclosure This preliminary, unaudited performance forecast advises investors to exercise caution, with full financial details to be disclosed in the upcoming 2025 semi-annual report IV. Other Related Explanations This performance forecast is a preliminary estimate by the company's finance department, unaudited by an accounting firm; specific financial data will be detailed in the company's 2025 semi-annual report, and investors are advised to make cautious decisions and be aware of investment risks - This performance forecast is a preliminary estimate by the company's finance department and has not been audited by an accounting firm[6] - Specific financial data will be detailed in the company's 2025 semi-annual report[6] - Investors are advised to make cautious decisions and be aware of investment risks[6][7]